[go: up one dir, main page]

NO995236D0 - Nerve-vekstfaktor som vaksine-adjuvant - Google Patents

Nerve-vekstfaktor som vaksine-adjuvant

Info

Publication number
NO995236D0
NO995236D0 NO995236A NO995236A NO995236D0 NO 995236 D0 NO995236 D0 NO 995236D0 NO 995236 A NO995236 A NO 995236A NO 995236 A NO995236 A NO 995236A NO 995236 D0 NO995236 D0 NO 995236D0
Authority
NO
Norway
Prior art keywords
vaccine
growth factor
nerve growth
animal
vaccine adjuvant
Prior art date
Application number
NO995236A
Other languages
English (en)
Other versions
NO326022B1 (no
NO995236L (no
Inventor
Maria Torcia
Original Assignee
Protechtion Unlimited Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protechtion Unlimited Inc filed Critical Protechtion Unlimited Inc
Publication of NO995236D0 publication Critical patent/NO995236D0/no
Publication of NO995236L publication Critical patent/NO995236L/no
Publication of NO326022B1 publication Critical patent/NO326022B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO19995236A 1997-05-01 1999-10-26 Farmasoytisk kombinasjon til forsterkning av vaksine-effetiviteten hos immunodefekte dyr, samt anvedelse av vaksinen pa immunodefekte dyr NO326022B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84722897A 1997-05-01 1997-05-01
PCT/US1998/008652 WO1998048832A1 (en) 1997-05-01 1998-04-30 Nerve growth factor as a vaccine adjuvant

Publications (3)

Publication Number Publication Date
NO995236D0 true NO995236D0 (no) 1999-10-26
NO995236L NO995236L (no) 1999-12-10
NO326022B1 NO326022B1 (no) 2008-09-01

Family

ID=25300123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995236A NO326022B1 (no) 1997-05-01 1999-10-26 Farmasoytisk kombinasjon til forsterkning av vaksine-effetiviteten hos immunodefekte dyr, samt anvedelse av vaksinen pa immunodefekte dyr

Country Status (14)

Country Link
US (1) US6572866B1 (no)
EP (1) EP0994721B1 (no)
JP (1) JP4205172B2 (no)
CN (1) CN1128637C (no)
AT (1) ATE346606T1 (no)
AU (1) AU727652B2 (no)
CA (1) CA2289040A1 (no)
CY (1) CY1107571T1 (no)
DE (1) DE69836543T2 (no)
DK (1) DK0994721T3 (no)
ES (1) ES2278411T3 (no)
NO (1) NO326022B1 (no)
PT (1) PT994721E (no)
WO (1) WO1998048832A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011203139B2 (en) * 1998-02-27 2014-06-19 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
TWI358301B (en) * 2003-07-11 2012-02-21 Intercell Ag Hcv vaccines
KR20070048140A (ko) * 2004-06-15 2007-05-08 더 뉴욕 블러드 센터, 인코포레이티드 온코세르카 볼불러스의 천연 생성물의 항원보강성 및 면역강화 특성
EP1809336B1 (en) * 2004-07-23 2008-11-12 Advisys, Inc. Growth hormone releasing hormone enhances the immune response induced by vaccination
WO2006116053A1 (en) * 2005-04-22 2006-11-02 Sciclone Pharmaceuticals, Inc. Immunomodulator compounds as vaccine enhancers
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP3058954B1 (en) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
ES2552858T3 (es) 2007-10-01 2015-12-02 Longhorn Vaccines And Diagnostics, Llc Recogida de muestras biológicas y sistema de transporte y métodos de uso
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US8321012B2 (en) 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
EP2950095B1 (en) * 2014-05-28 2018-08-29 Technische Universität Dresden Cell-based assay and screening methods for modulators of p75NTR signaling
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
GB2615470A (en) 2020-10-20 2023-08-09 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant

Also Published As

Publication number Publication date
US6572866B1 (en) 2003-06-03
AU7266498A (en) 1998-11-24
CY1107571T1 (el) 2013-03-13
CA2289040A1 (en) 1998-11-05
NO326022B1 (no) 2008-09-01
WO1998048832A1 (en) 1998-11-05
EP0994721B1 (en) 2006-11-29
ATE346606T1 (de) 2006-12-15
PT994721E (pt) 2007-03-30
DK0994721T3 (da) 2007-04-02
JP4205172B2 (ja) 2009-01-07
EP0994721A1 (en) 2000-04-26
CN1128637C (zh) 2003-11-26
DE69836543D1 (de) 2007-01-11
EP0994721A4 (en) 2003-08-27
ES2278411T3 (es) 2007-08-01
CN1260722A (zh) 2000-07-19
NO995236L (no) 1999-12-10
DE69836543T2 (de) 2007-09-20
AU727652B2 (en) 2000-12-21
JP2002500638A (ja) 2002-01-08

Similar Documents

Publication Publication Date Title
CY1107571T1 (el) Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
EP0855918A4 (en) INTERLEUKIN-15 FROM CHICKENS AND ITS USE
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
DE68924162D1 (de) Stressproteine und verwendungen dafür.
LU92262I2 (fr) Vaccin méningococcique groupe B (ADNr, composant, adsorbé) et ses dérivés pharmaceutiquement acceptables (BEXSERO)
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
ATE411043T1 (de) Verfahren von dna-impfung
NO950739L (no) Vaksiner mot gruppe C Neisseria Meningtidis
EP0722338A4 (en) Vaccines consisting of protein or peptide "cochlates" and their use for immunization
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
ATE284613T1 (de) Polynukleotid-impfstoff-formulierungen
EP0259324A4 (en) Mastitis vaccine.
BR9815404A (pt) Composição adjuvante para estimular uma eficiente resposta imunológica a uma substância antigênica, vacina para administração a um animal, processo para estimular uma resposta imunológica eficaz em um animal a uma substância antigênica, e, uso da composição adjuvante.
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
BR9808878A (pt) Imunização contra moléculas endógenas
UA38678A (uk) Засіб для підвищення імунобіологічної реактивності та метаболізму організму тварин

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees